Alirocumab Significantly Downs Cholesterol in HoFH Patients

PCSK9 inhibitor named Alirocumab is evaluated for treating patients with homozygous familial hypercholesterolemia (HoFH).

from Medindia Health News https://ift.tt/2JpN83l